https://www.youtube.com/watch?v=xbjwRLoQwtw
Learn how to perform manual and automated purification of circulating cell-free DNA from plasma samples. Throughout the process, magnets are utilized to isol

https://www.nature.com/articles/s41598-021-98815-x
Schematic of DNA isolation process with PHASIFY MAX and PHASIFY ENRICH. The PHASIFY method uses serial two-phase liquid extraction systems to isolate and purify cfDNA from a starting plasma sample.

https://www.qiagen.com/us/applications/liquid-biopsy/cell-free-dna
Found in low concentrations, cfDNA contains only 1-2% circulating tumor DNA (ctDNA) in non-advanced, non-metastatic cancers. Isolation of cfDNA from low concentrations with high background noise requires handling of large starting volumes. High yields and purity are required for sensitive and reliable detection and analysis.

https://www.nature.com/articles/s41698-019-0107-0
Cell-free DNA (cfDNA) has been implicated as an important biomarker in cancer management. Thus, efficient techniques for cfDNA extraction are necessary for precision medicine. We developed a

https://www.thermofisher.com/us/en/home/life-science/dna-rna-purification-analysis/automated-purification-extraction/automated-magmax-kits-nucleic-acid-extraction/cell-free-dna-cfdna-isolation.html
Cell-free DNA (cfDNA) refers to fragments of DNA that are found circulating freely in the bloodstream or other bodily fluids. Types of cfDNA include circulating tumor DNA (ctDNA), cell-free fetal DNA (cffDNA), cell-free mitochondrial DNA (ccf mtDNA), and donor-derived cell-free DNA (dd-cfDNA). Efficient nucleic acid isolation that specifically

https://www.nature.com/articles/s41431-018-0132-4
European Journal of Human Genetics - Circulating cell-free nucleic acids: characteristics and applications ... (EMVS), cell-free DNA (cfDNA), cell-free RNA (cfRNA) and proteins that can be used as

http://www.picardlab.org/uploads/7/7/8/4/77845210/trumpff_2021_mitochondrion_protocol.pdf
Draw required volume of blood for cf-DNA measurements (ideally 5 mL or more)1. Immediately (within 2 minutes, if possible) centrifuge anticoagulated blood at 1,000 x g for. 5 minutes at room temperature. Blood will separate into three layers: the bottom layer is red blood cells, the top layer is plasma, and the interface is the buffy coat.

https://digitalinsights.qiagen.com/news/blog/clinical/circulating-cfdna-purification-sequencing-and-data-interpretation/
Circulating cell-free DNA purification, sequencing and data interpretation. Identification and monitoring of cancer mutations of circulating cell-free DNA (cfDNA) is a key application in liquid biopsy. In this webinar series, we will discuss various new technologies and present a complete sample to insight workflow for cfDNA mutation analysis.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650475/
Cell-free DNA (cfDNA) can be used as a liquid biopsy in neuro-oncology. New applications harnessing the biological patterns of cfDNA improved detection. This review will provide the basis to understand and use cfDNA biological signatures. Liquid biopsy, and cell-free DNA (cfDNA) in particular, have been intensively investigated for diagnostic

https://videos.thermofisher.com/detail/video/5152740822001/how-to-purify-circulating-cell-free-dna
Learn how to perform manual and automated purification of circulating cell-free DNA from plasma samples. Throughout the process, magnets are utilized to isolate the DNA, making the protocol simple and scalable. View More.

https://www.nvigen.com/cfdna-extraction-tutorial/
Cell-free DNA (cfDNA) are degraded DNA molecules/fragments that are released into the bloodstream by cells. These fragments, which can vary in length between 50 and 300 base pairs, are no longer confined or encapsulated inside a cell but circulating freely in the bloodstream. Hence it's called cell-free DNA.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431421/
1. cfDNA—Historical Perspective. Circulating cell-free DNA (cfDNA) are extracellular fragments of DNA present in body fluid that may be derived from both normal and diseased cells []. cfDNA molecules were discovered in the human circulatory system in 1948 by Mandel and Metais [].Seventeen years later, in 1965, Bendich et al. [] hypothesized that cancer-derived cfDNA was a determining factor

https://www.idtdna.com/pages/community/blog/post/cfdna-extraction-here-s-what-you-need-to-know
Cell-free DNA extraction is a laboratory process that involves isolating and purifying DNA fragments that circulate freely in the bloodstream or other bodily fluids. cfDNA is derived from cells undergoing apoptosis (a process that causes a cell to die), necrosis (uncontrolled cell death that results in tissue damage), or actively releasing

https://en.wikipedia.org/wiki/Circulating_free_DNA
Circulating free DNA (cfDNA) (also known as cell-free DNA) are degraded DNA fragments released to body fluids such as blood plasma, urine, cerebrospinal fluid, etc. Typical sizes of cfDNA fragments reflect chromatosome particles (~165bp), as well as multiples of nucleosomes, which protect DNA from digestion by apoptotic nucleases. The term cfDNA can be used to describe various forms of DNA

https://pubmed.ncbi.nlm.nih.gov/30580420/
The study of cell-free DNA (cfDNA) is often challenging due to genomic DNA contamination, low concentration, and high fragmentation. Therefore, it is important to optimize pre-analytical and analytical procedures in order to maximize the performance of cfDNA-based analyses.In this chapter, we report the most common methods for the correct collection, centrifugation, storage, and DNA isolation

https://www.qiagen.com/us/knowledge-and-support/knowledge-hub/bench-guide/cell-free-dna-guide/handling-cfdna/preanalytical-handling-and-cfdna-stability
Plasma preparation using PAXgene Blood ccfDNA Tubes. Store for up to 10 days at up to 25°C; up to 7 days at up to 30°C or up to 3 days at up to 37°C. Centrifuge for 15 min at room temperature and 1600-3000 x g. Carefully aspirate the supernatant. Centrifuge for 10 min at room temperature and 1600-3000 x g.

https://link.springer.com/protocol/10.1007/978-1-4939-8973-7_2
Cell-free DNA (cfDNA) consists in extracellular DNA fragments which are shed into biological fluids by necrotic and apoptotic cells [].The typical biological source for the isolation of cfDNA is the bloodstream, but it is possible to obtain it also from other biological materials such as urines [2,3,4], cerebrospinal fluid (CSF) [5,6,7], and pleural effusion fluid (PEF) [8,9,10,11].

https://www.nature.com/articles/s41598-018-23766-9
Extraction of cell-free DNA (cfDNA), which exists at an extremely low concentration in plasma, is a critical process for either targeted-sensing or massive sequencing of DNAs. However, such small

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606043/
Levels of cell-free DNA. cfDNA was first described in immune complexes derived from patients with systemic lupus erythematosus in 1948, 30 but serum cfDNA levels from patients with cancer were characterized for the first time 30 years later. 31 It was shown that the total amount of circulating DNA was higher in patients with cancer than in healthy subjects. 31, 32 However, an increased cfDNA

https://www.biorxiv.org/content/10.1101/2024.03.25.586507v1
Plasma cell-free DNA (cfDNA) is derived from cellular death in various tissues. Investigating the origin of cfDNA through tissue/cell type deconvolution allows us to detect changes in tissue homeostasis that occur during disease progression or in response to treatment. Consequently, cfDNA has emerged as a valuable noninvasive biomarker for disease detection and treatment monitoring.

https://academic.oup.com/nar/article/52/11/e50/7680632
Although many biomolecules (e.g. circulating tumor cells, exosomes, proteins, RNAs, or metabolites) are viable for liquid biopsy, there has been a focus in prior studies on cell-free DNA (cfDNA). Examining methylation characteristics inherent within cfDNA fragments is a promising approach (4, 5). Dysregulated epigenetic control in tumor cells

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133648/
Strategies for early detection of cancers are generally based on the detection of cancer-related alterations in the cfDNA released from cancer cells, known as circulating tumor DNA (ctDNA). The concentration of ctDNA in plasma is relatively low and accounts for less than 0.01% of the total cfDNA concentration, 1040 especially in early-stage

https://link.springer.com/article/10.1007/s10528-024-10849-8
The identification of novel non-invasive biomarkers is imperative for the early diagnosis and monitoring of malignant melanoma. The objective of this study is to examine the expression levels of miR-155-5p, miR-181b-5p, and miR-454-3p in circulating cell-free RNA obtained from plasma samples of the 72 uveal malignant melanoma patients and to compare these levels with those of 72 healthy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601152/
Plasma cell-free DNA (cfDNA) originates from various tissues and cell types and can enable minimally invasive diagnosis, treatment and monitoring of cancer and other diseases. ... Rizos H. Evaluation of commercial kits for purification of circulating free DNA. Cancer Genet. 2018; 228-229:21-27. doi: 10.1016/j.cancergen.2018.08.005. [Google

https://www.businesswire.com/news/home/20240627607646/en/Natera-Announces-DECIPHER-A-Phase-II-Single-Arm-Adjuvant-Trial-in-Gastroesophageal-Cancer
Natera TM is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of